Literature DB >> 19896789

MRI for the size assessment of pure ductal carcinoma in situ (DCIS): a prospective study of 33 patients.

C Marcotte-Bloch1, C Balu-Maestro, E Chamorey, F Ettore, I Raoust, B Flipo, C Chapellier.   

Abstract

OBJECTIVE: To determine whether MRI assesses the size of ductal carcinomas in situ (DCIS) more accurately than mammography, using the histopathological dimension of the surgical specimen as the reference measurement.
MATERIALS AND METHODS: This single-center prospective study conducted from March 2007 to July 2008 at the Antoine-Lacassagne Cancer Treatment Center (Nice, France) included 33 patients with a histologically proven DCIS by needle biopsy, who all underwent clinical examination, mammography, and MRI interpreted by an experienced radiologist. All patients underwent surgery at our institution. The greatest dimensions of the DCIS determined by the two imaging modalities were compared with the histopathological dimension ascertained on the surgical specimen. The study was approved by the local Ethical Research Committee and was authorized by the French National Health Agency (AFSSAPS).
RESULTS: The mean age of the 33 patients was 59.7 years (± 10.3). Three patients had a palpable mass at clinical breast examination; 82% underwent conservative surgical therapy rather than radical breast surgery (mastectomy); 6% required repeat surgery. MRI detected 97% of the lesions. Non-mass-like enhancement was noted for 78% of the patients. In over 50% of the cases, distribution of the DCIS was ductal or segmental and the kinetic enhancement curve was persistent. Lesion size was correctly estimated (± 5 mm), under-estimated (<5mm), or over-estimated (>5mm), respectively, by MRI in 60%, 19% and 21% of cases and by mammography in 38%, 31% and 31% (p = 0.05). Mean lesion size was 25.6mm at histopathology, 28.1mm at MRI, and 27.2mm on mammography (nonsignificant difference). The correlation coefficient between histopathological measurement and MRI was 0.831 versus 0.674 between histopathology and mammography. The correlation coefficient increased with the nuclear grade of the DCIS on mammography; this coefficient also increased as the mammographic breast density decreased.
CONCLUSION: MRI appears to assess the size of DCIS better than mammography by limiting the number of under- and over-estimations compared to histopathology findings.
Copyright © 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19896789     DOI: 10.1016/j.ejrad.2009.09.003

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  13 in total

1.  Value of pre-operative breast MRI for the size assessment of ductal carcinoma in situ.

Authors:  Francesca Proulx; José A Correa; Romuald Ferré; Atilla Omeroglu; Ann Aldis; Sarkis Meterissian; Benoît Mesurolle
Journal:  Br J Radiol       Date:  2015-11-16       Impact factor: 3.039

2.  The role of breast MR imaging in pre-operative determination of invasive disease for ductal carcinoma in situ diagnosed by needle biopsy.

Authors:  Mariko Goto; Sachiko Yuen; Kentaro Akazawa; Kaori Nishida; Eiichi Konishi; Mariko Kajihara; Nobuhiko Shinkura; Kei Yamada
Journal:  Eur Radiol       Date:  2011-12-30       Impact factor: 5.315

Review 3.  Advances in Breast MRI in the Setting of Ductal Carcinoma In Situ.

Authors:  Nita Amornsiripanitch; Diana L Lam; Habib Rahbar
Journal:  Semin Roentgenol       Date:  2018-08-30       Impact factor: 0.800

4.  Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance).

Authors:  E Shelley Hwang; Terry Hyslop; Laura H Hendrix; Stephanie Duong; Isabelle Bedrosian; Elissa Price; Abigail Caudle; Tina Hieken; Joseph Guenther; Clifford A Hudis; Eric Winer; Alan P Lyss; Diana Dickson-Witmer; Richard Hoefer; David W Ollila; Timothy Hardman; Jeffrey Marks; Yunn-Yi Chen; Gregor Krings; Laura Esserman; Nola Hylton
Journal:  J Clin Oncol       Date:  2020-03-03       Impact factor: 44.544

5.  Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ.

Authors:  Anna F Meyerson; Juan N Lessing; Kaoru Itakura; Nola M Hylton; Dulcy E Wolverton; Bonnie N Joe; Laura J Esserman; E Shelley Hwang
Journal:  Breast       Date:  2011-08-16       Impact factor: 4.380

Review 6.  Current and future applications of magnetic resonance imaging (MRI) to breast and ovarian cancer patient management.

Authors:  Jim Klostergaard; Kenia Parga; Raphael G Raptis
Journal:  P R Health Sci J       Date:  2010-09       Impact factor: 0.705

7.  Accuracy of 3 T versus 1.5 T breast MRI for pre-operative assessment of extent of disease in newly diagnosed DCIS.

Authors:  Habib Rahbar; Wendy B DeMartini; Amie Y Lee; Savannah C Partridge; Sue Peacock; Constance D Lehman
Journal:  Eur J Radiol       Date:  2015-01-08       Impact factor: 3.528

Review 8.  The accuracy of magnetic resonance imaging in predicting the size of pure ductal carcinoma in situ: a systematic review and meta-analysis.

Authors:  Ricardo Roque; Mariana Robalo Cordeiro; Mónica Armas; Francisco Caramelo; Filipe Caseiro-Alves; Margarida Figueiredo-Dias
Journal:  NPJ Breast Cancer       Date:  2022-06-29

9.  Overcoming Barriers in Ductal Carcinoma In Situ Management: From Overtreatment to Optimal Treatment.

Authors:  Jean L Wright; Habib Rahbar; Samilia Obeng-Gyasi; Ruth Carlos; Judy Tjoe; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2021-11-23       Impact factor: 50.717

10.  The role of magnetic resonance imaging in preoperative planning for patients undergoing therapeutic mammoplasty.

Authors:  Gareth Hicks; Philip Turton; Sree Rajan; April Nunn; Nisha Sharma; Raj Achuthan
Journal:  ISRN Oncol       Date:  2013-12-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.